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ABSTRACT 
 
The multifunctional, protein cross-linking transglutaminase 2 (TG2) is the main autoantigen in 
celiac disease, an autoimmune disorder with defined etiology.  Glutamine-rich gliadin peptides 
from ingested cereals, after their deamidation by TG2, induce T-lymphocyte activation 
accompanied by autoantibody production against TG2 in 1-2% of the population. The pathogenic 
role and exact binding properties of these antibodies to TG2 are still unclear. Here we show that 
antibodies from different celiac patients target the same conformational TG2 epitope formed by 
spatially close amino acids of adjacent domains. Glu153 and 154 on the first alpha-helix of the 
core domain and Arg19 on first alpha-helix of the N-terminal domain determine the celiac epitope 
which is accessible both in the closed and open conformation of TG2 and dependent on the 
relative position of these helices. Met659 on the C-terminal domain also can cooperate in antibody 
binding. This composite epitope is disease-specific, recognized by antibodies derived from celiac 
tissues and associated with biological effects when passively transferred from celiac mothers into 
their newborns. These findings suggest that celiac antibodies are produced in a surface-specific 
way for which certain homology of the central glutamic acid residues of the TG2 epitope with 
deamidated gliadin peptides could be a structural basis. Monoclonal mouse antibodies with 
partially overlapping epitope specificity released celiac antibodies from patient tissues and 
antagonized their harmful effects in cell culture experiments. Such antibodies or similar specific 
competitors will be useful in further functional studies and in exploring whether interference with 
celiac antibody actions leads to therapeutic benefits.   
 
Abbreviations: aa, amino acids, EMA, endomysial antibodies, HUVEC, human umbilical cord 
vein endothelial cells, mAb, monoclonal mouse antibody, ScFv, single-chain variable fragments, 
TG2, transglutaminase type-2 
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INTRODUCTION 
Transglutaminase 2 (TG2, ‘tissue’ transglutaminase, EC 2.3.2.13) is an ubiquitous cellular protein 
also present in the extracellular matrix where it catalyzes Ca2+-dependent protein cross-linking via 
N’(γ-glutamyl)lysine bonds or the deamidation of glutamine residues. In addition, TG2 also has 
pleitropic intracellular functions as GTP-ase, protein disulphide isomerase, serine/threonine kinase 
and acts as adaptor on the cell surface for fibronectin, integrins, syndecan 4 and other matrix 
proteins regulating cell adhesion, differentiation and survival (1). TG’s complex structure and  
high sensitivity to ligand-induced conformational changes (2) makes challenging to dissect the 
structural basis for these interactions, and only the fibronectin binding site on the loop with amino 
acids (aa) 94 and 97 (3) is known in details. Contradictory data exist also on the epitope 
recognized by TG2-specific antibodies produced in celiac disease (celiac sprue), an autoimmune 
condition resulting from intolerance to gluten-containing cereals (wheat, rye, barley) that induce 
after their TG2-mediated deamidation specific T lymphocyte activation, intestinal inflammation 
and villous atrophy in genetic susceptible individuals carrying HLA-DQ2 or DQ8 (4).  
Celiac antibodies exert biological effects via TG2, partly by gain in catalytic activity, on epithelial 
cell differentiation (5) and transport (6), angiogenesis (7), vascular permeability (8), monocyte 
activation (9), cell cycle progression (10) and apoptosis (11) in cell culture experiments, and 
presumably also in vivo, but direct evidence for the latter has not been yet provided. Animal 
models remained incomplete (12) and IgA anti-TG2 antibodies similar to those in patients’ serum 
(13) and bound in different tissues in a greatly specific pattern along vessels and TG2-rich 
endomysium (14) were not produced. A gluten-free diet normalizes the gut lesions and eliminates 
TG2 antibodies from both serum and tissues. Such a life-long diet is difficult to maintain and 
therefore exploration of alternative treatment modalities is in progress.  
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The monomeric human TG2 consists of four structural domains (N-terminal β–sandwich, core, and 
two C-terminal β–barrels) (1). In the presence of GDP, TG2 shows a closed conformation with the 
transamidating catalytic triad on the core domain in a hidden position (PDB code: 1KV3) (15). 
When TG2 is functioning as a Ca2+-dependent transglutaminase, C-terminal beta-barrels are 
displaced by 120 Å and the structure becomes open and extended (2) (PDB code: 2Q3Z), at least 
transiently. In earlier studies celiac anti-TG2 antibodies bound to multiple (often complementary) 
fragments of human TG2 (16,17,18), but to none of linear TG2 peptides expressed in phage 
display (19). In another study, mutagenesis of the normally buried catalytic triad decreased 
antibody binding (20). Celiac antibodies do not bind well in Western blot (13) or in paraffin-
embedded tissues indicating conformation dependency of antibody recognition.  Here we describe 
a single conformational TG2 epitope important for all investigated celiac patient samples and 
potential target for immunotherapy. This celiac epitope involves the first alpha-helix of the N-
terminal domain, the first alpha-helix of the core domain and, additionally, the C-terminal domain. 
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RESULTS 
Binding of celiac antibodies is related to a calcium binding site on the core domain of TG2 
but does not require calcium ions  
We recently identified two adjacent novel Ca2+ binding sites on the core domain of TG2, S4 (aa 
151-158) and S5 (aa 433-438), of which S4 strongly determines antigenicity for celiac antibodies 
(21). As these results were generated with multiple mutations of acidic glutamate and aspartate 
residues in these regions, we wished to precisely identify the anchor residues that form a celiac 
epitope. We prepared now TG2 molecules bearing D151N, E153Q, E154Q, E155Q, E158Q, 
E158L and R433S-E435S mutations separately. From these, only changes at residue 158 abolished 
the binding of celiac antibodies (Fig.1), but 158 is not surface-exposed and its mutations were 
found to have only indirect effect on the position of the helix formed by the S4 site amino acids. 
Lack of binding to TG2 denatured with urea (Fig. S1A) indeed confirmed that celiac 
autoantibodies do not bind to a linear epitope. A mutation on the surface in Glu153 had significant 
(p<0.0001) but only moderate effect, so Glu153 could be one potential anchor point for the 
binding of celiac antibodies, which, however, might need cooperation with other surface structures 
to form an epitope. Ca2+ ions themselves did not contribute to the formation of the celiac epitope as 
shown in supporting information (SI) text and Fig.S1B.  
 
Analysis of further binding sites outside the core domain 
We next used TG2 mutants each lacking one structural domain of TG2 (22) to locate celiac 
antibody binding sites further to S4. Previous studies (2,3) indicate that the N-terminal domain (I) 
expressed alone, and also domains III and IV, will adopt a functional conformation independently 
of the core (II) domain. When the domain mutants were applied in equimolar concentrations in 
immunoassays, both domain I and II turned out to be important for autoantibody binding (Fig.1), 
and antibody recognition was also influenced by the loss of domain IV (aa 585-687) but not at all 
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by the absence of domain III (aa 472-584). These results suggested, in accordance with previous 
data (16-18), that parts of celiac epitopes are found both on the N-terminal and C-terminal 
domains. Importantly, patient antibodies, however, did not bind to the mutant containing only 
domains I-III-IV but not domain II, so in the absence of the anchor points on the core domain the 
other celiac epitope parts were not capable to form a functional binding site. 
 
Three anchor points determine a composite epitope formed by three distinct domains and 
two of these are sufficient for binding of celiac antibodies  
Molecular modelling was used to evaluate whether cooperation of core domain Glu153 with other 
amino acids on the N-terminal and/or C-terminal domains might form functional epitopes. In the 
resting (closed) conformation of TG2 shown by X-ray crystallography (1KV3) (15), the N- and C-
terminal parts of the molecule are close to each other and to the surface of the core domain. Core 
domain Glu153 is in the closest proximity to N-terminal domain Arg19 (12.9 Ǻ) and C-terminal 
domain Met659 (16.8 Ǻ), and moreover, Arg19 is also close to Met659 (7.7 Ǻ) forming possibly a 
common conformational epitope (Fig.2). Each single mutation of these amino acids to serine (R, 
R19S; E, E153S; M, M659S) resulted in significant decrease in celiac antibody binding (26.5%, 
28.8% and 56.9% remaining binding for R, E and M, respectively; Fig.3A) and combined 
mutations caused proportionally greater changes (6.6%, 21.7%, 14.6% and 13.4% remaining 
binding for RE, EM, RM and REM, respectively). The bindings of autoantibodies from 
consecutively diagnosed 58 childhood (Fig.3A) and 18 adult celiac patients (Fig.3B) as well as of 
all 8 tested single chain monoclonal antibody clones (ScFv) (23) originating from celiac patients 
(Fig.S3A) were abolished when mutants RE and REM were applied as antigens. Despite of the 
decreased binding of celiac antibodies, these mutant TG2 proteins bound normally a large set (22) 
of mouse monoclonal anti-TG2 antibodies, showed appropriately folded structures in CD spectra 
and functionality in fibronectin binding, transglutaminase and GTPase assays (Fig.S2A-D). 
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Further experiments with Factor XIII homologous mutants targeting Glu154 (SI Text and 
Fig.S3B,C) supported that celiac antibodies directly bind to the TG2 surface delineated by Arg19-
Glu153-Met659. Anchor points homologous to Arg19, Glu153 and Glu154 were found by library 
search in those animal TG2 sequences and in human TG6 which are good celiac antigens (SI 
Table1), while blood coagulation Factor XIII, a related transglutaminase not antigenic in celiac 
disease (24), contains a positively charged Lys199 at position corresponding to Glu154.   
To establish the relative importance of Arg19 and Met659 in celiac antibody binding, we studied 
fibronectin-bound TG2 (25) as a model of accessibility of TG2 epitopes in the extracellular matrix 
where antibodies primarily encounter the autoantigen in patients. Under these conditions, the 
mutations of Arg19 and Glu153 had similar effects as seen above (Fig.S3D), but mutation of 
Met659 alone did not alter celiac antibody binding and so celiac antibodies may bind to TG2 also 
in its catalytically active form when TG2 adopts an open-extended conformation where domain IV 
with Met659 swings out (2). Measurements on the position of Arg19 and Glu153 in this open form 
crystal structure (2Q3Z) did not show a difference in distance as compared to the closed 
conformation (1KV3)(Fig.S3E). 
 
Antibodies of different celiac patients recognize parts of the same epitope 
Although all celiac patient serum samples displayed a severely reduced binding to REM triple and 
RE double mutants, their reaction showed some variability with the point mutant where only the 
N-terminal anchor point (Arg19) had been changed (Fig.3). Celiac patient-derived monoclonal 
ScFvs expressed from phage libraries (23) belonged to two groups as well, one reacting with R19S 
and one not (Fig.S4A). However, ScFvs belonging to either group showed greatly reduced binding 
to Glu153 (E153S) or Glu154 (E154K) mutants and competed with each other for the binding to 
wild-type TG2 (SI Text and Fig.S4B). IgA and IgG antibodies differently recognizing R19S were 
purified from sera of celiac patients (25), and these competed as well with each other but not with 
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non-celiac human IgG (Fig.S4C). Further, we were able to develop a diagnostic ELISA with 98% 
sensitivity and 96% specificity for measuring IgG class celiac antibodies in subjects with selective 
humoral IgA deficiency by their concentration-dependent displacement effect (r=0.88) on a known 
celiac IgA tracer antibody (Fig.S4D,E).  
 
Disease specificity of the composite TG2 epitope 
During the development of celiac disease, both early cases during the latent stage when villous 
atrophy was not yet present and at diagnosing villous atrophy showed low reactivity to Glu153 and 
Arg19 mutants without statistical difference (Fig.4). Interestingly, no or only limited epitope 
spreading occurred during a follow-up for up to 17 years without proper diet or upon later 
diagnostic gluten challenge (Fig.S5).  The serum samples from patients with other autoimmune 
diseases (SLE, Sjögren’s syndrome, rheumatoid arthritis, See SI Text for details) containing non-
celiac anti-TG2 antibodies but negative for anti-endomysial or anti-deamidated gliadin antibodies 
showed a clearly different binding pattern to the celiac epitope (Fig.4). Monoclonal TG2-specific 
mouse antibodies (mAb) 885 (Phadia, Uppsala, Sweden) which had previously been found to 
target Glu153 (Fig.S7) selectively interfered with the binding of celiac antibodies to wild-type 
TG2, but they did not compete with the binding of non-celiac TG2 antibodies (Fig.5). These data 
collectively suggest that celiac disease results in a particular and directed immune response 
towards TG2.   
 
The composite TG2 epitope mediates in vivo tissue-binding of celiac antibodies and their 
biological effects   
In order to explore whether the identified composite epitope is also important under in vivo 
conditions, we performed binding studies with antibodies isolated from celiac tissues (Fig.6). An 
extraintestinal tissue was chosen for this experiment to avoid contamination with non-specific IgA 
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present in gut plasma cells. Placenta specimens were available from two celiac mothers and both 
contained high amounts of TG2-bound maternal IgA antibodies in the wall of decidual blood 
vessels and on the surface of the chorionic villous structures (Fig.S6). This IgA was eluted with 
chloroacetic acid (14) and showed epitope targeting pattern identical to the typical one observed 
with celiac serum samples, as described above (Fig.6A). Further, frozen placenta sections were 
subjected to competition studies with mAb 885 and control mAbs. After incubation with excess 
amounts of mAb 885 but not with buffer only or with isotype control mouse antibodies (Dako), in 
vivo tissue-bound anti-TG2 IgA antibodies completely disappeared from the tissue as shown by 
immunostainings  and were released into the buffer (Fig.6B).  After incubation of celiac tissues 
with CUB7402 anti-TG2 mAb targeting a different TG2 epitope, celiac IgA remained unchanged 
and did not appear in the buffer (Fig.6B).  
Since there is an altered vasculature in the celiac small bowel mucosa and celiac antibodies deposit 
around vessels, a defective angiogenesis was suggested to contribute to the architectural changes 
eventually leading to mucosal flattening (7). Therefore, we investigated the differentiation of 
commercial human umbilical cord vein endothelial cells (HUVEC) in matrigel as a standard 
angiogenesis assay (26).  In this assay, purified IgA from autoimmune patients with non-celiac 
TG2 antibodies caused only slight non-specific descrease in endothelial tubule formation similarly 
to control IgA from antibody-negative healthy persons, but celiac IgA significantly decreased 
tubule length (Fig.6C) and formation (Fig.S7C) and this effect was prevented in the presence of 
mAb 885. Similar effect was observed on cell lengths when mAb 885 was co-administered with 
purified monospecific celiac ScFvs to HUVEC cells grown on collagen I (Fig. S7D). 
 
Maternal celiac antibodies transferred into newborns have biologic effects   
In parallel of antibody deposition in the placenta (Fig.6B), maternal IgG anti-TG2 antibodies were 
detected also in the umbilical cords and sera of the newborns, and on the surface of HUVECs 
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isolated from the umbilical cord (Fig.6E). These antibodies had the same epitope specificity as 
antibodies of their mothers (Fig.6A), but as expected, IgA autoantibodies did not cross the 
placenta. HUVEC cells exposed to maternal antibodies before birth displayed abnormalities in 
their shape and spreading, and lived for shorter time in culture compared to cells isolated from 
babies with antibody-negative celiac mothers (Fig.6E and S6). These cellular changes were similar 
to those we observed earlier when celiac IgA was added to normal HUVEC cultures (7).  
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DISCUSSION 
The results presented here show a particular uniformity of gluten-driven autoantibody production 
in celiac disease towards one main conformational celiac TG2 epitope, characteristic for both 
serum antibodies and tissue-derived monoclonal antibodies. In contrast, TG2 antibodies from 
subjects with other autoimmune diseases prefer other binding sites. These findings make possible 
to design interfering compounds for further research and with potential to explore therapeutic use. 
The main anchors points of this celiac epitope are Glu153 and Glu154 on the edge of the 
first alpha helix of the core domain of TG2, but they also need one more anchor point either on the 
N-terminal or C-terminal domains. The N-terminal anchor point is formed by the first helix 
containing Arg19. Arginins often form part of epitopes, and cooperation of Glu153 with Arg19 is 
predicted to be an energetically favorable binding site resulting in a large change in solvent-
accessible surface area after antibody binding (27). The position of these two anchor points does 
not change during the opening of the enzyme upon its activation, so this epitope is accessible in 
tissues indepedently of the Ca2+-driven conformational shift, especially when TG2 is bound to 
fibronectin. Celiac antibodies bind well to both the Ca2+-bound and Ca2+-free TG2 (Fig.S1B) and 
to open-form TG2 (8) and TG2 transamidates substrates even in the presence of bound celiac 
antibodies (28). These observations strongly contradict the earlier suggestion (20) that the catalytic 
triad, situated buried and exposed on the surface just when Ca2+ and substrates are available, 
would compose the celiac epitope.  
As an alternative to Arg19 from the N-terminal domain, Glu153 also may cooperate with 
Met659 on the C-terminal domain, explaining earlier epitope mapping results with some C-
terminal TG2 fragments (16,17). Accordingly, Arg19 was not indispensable for the binding of 
serum antibodies of all our celiac patients, nor for certain patient-derived phage antibodies 
provided the C-terminal domains were present. The competition between different ScFv-groups or 
natural IgA and IgG patient antibodies recognizing Arg19 differently and effective displacement 
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of diverse patient antibodies by mAb 885 targeting only Glu153 demonstrates that Glu153, Arg19 
and Met659 constitute one composite epitope when the protein is in the closed conformation. 
Binding of celiac antibodies to a surface area close to the interface of  adjacent domains may be 
the structural basis for certain conformation stabilizing effect responsible for the earlier observed 
gain in catalytic activity in the presence of celiac antibodies (8,25). The variable involvement of 
N-terminal and C-terminal domains explains why earlier studies typically found a sufficient 
binding if either the N-terminal or C-terminal TG2 parts were missing, but not if both were 
missing or if the core domain had been disrupted (16-18). We applied a special precaution to avoid 
the disruption of hydrogen bonds or the distorsion of the conformation, and the folded structure of 
our key mutants were confirmed by CD spectra. The results with our domain deletion mutant I-III-
IV indeed confirm the essential role of the core domain, whereas individual variations in the extent 
of the actually targeted surface could explain some heterogeneity in binding to fragments with 
parts of the 3-dimensional epitope on several of them. 
The present identification of a celiac disease-specific epitope, already characteristic in the 
early (latent) stage, has also diagnostic importance. A test that combines measurement of antibody 
binding to wild-type TG2 and to one with modified celiac epitope could distinguish in future 
between celiac-type and nonspecific anti-TG2 antibodies seen in other autoimmune diseases, 
tumors or tissue injury (29).   
Our findings also show that gluten-derived gliadin peptides drive the celiac autoimmune 
response in an ordered and surface-specific way and epitope spreading is not common despite 
long-term disease. The primary antibody response in infants targets deamidated gliadin peptides 
(30) in which certain glutamines have been changed to glutamic acids. Some of these antibodies 
cross-reacted also with TG2 in an earlier study and TG2-specific mAbs recognized a complex of 
3-dimensionally shaped deamidated gliadin peptides indicating molecular mimicry (22). 
Interestingly, the distance and spatial arrangement of the side-chains of Glu153 and Glu154 central 
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in the here described TG2 epitope are similar to the side-chains of Gln and Glu residues of the 
most typical immunogenic gliadin peptide (PQPELPY) docked into HLA-DQ2 (Fig.S8 and SI 
text). Further studies may confirm experimentally the pathologic relevance of this observation.  
In the complex immunopathology of celiac disease where activated gliadin-specific T 
lymphocytes are held responsible for tissue damage (4), the role of anti-TG2 antibodies is still 
undefined and often debated. Some other autoantibodies are clearly pathogenic, e.g. in rheumatoid 
arthritis (31), pemphigus vulgaris (32), or myasthenia gravis (33). Celiac anti-TG2 antibodies have 
a number of adverse biological effects in cell culture and their tissue-binding to vessels was 
coincident in clinical studies with development of intestinal villous atrophy, liver, muscle and 
kidney damage, lymphadenopathy and brain atrophy (5-11,14). Passively transferred maternal 
antibodies targeting the celiac epitope affected the behaviour of endothelial cells prepared from the 
umbilical cords (Fig.6E, S6B) and some of the neonates also showed symptoms and low birth 
weight (SI Text). Further, the antibodies deposited on the surface of chorionic villi may alter TG2 
activity (34), impair nutrient import and may be responsible for the altered pregnancy outcome 
(35) in celiac disease. TG2 also has non-enzymatic functions in cell adhesion, speading and 
survival (1,3) where autoantibody effects also can be directly mediated via the celiac epitope. 
Celiac sprue is considered as a life-long disease and unless it is treated increased morbidity 
and mortality prevails (4). Since steady compliance with the gluten-free diet is difficult and often 
unsuccessful, other attractive alternatives have been proposed, e.g. oral protease supplementation 
for the gastrointestinal degradation of proline-rich gliadin peptides or inhibition of intestinal TG2 
activity to prevent deamidation and binding of gluten peptides to HLA-DQ2 or HLA-DQ8 
molecules, though proper TG2 inhibitors for such a purpose have not been found yet. Here we 
showed that tissue-deposited celiac autoantibodies, which could be associated with the multi-organ 
manifestation of the disease (14), can be displaced by a monoclonal antibody recognizing part of 
the main celiac epitope characterized in this study. Furthermore, this displacing antibody did not 
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alter the enzymatic activity of TG2 (Fig.S7) nor had the typical pathologic effects elicited by 
celiac antibodies in cell culture experiments and could even antagonize the latters. These findings 
raise the possibility that the adverse pathologic effect of celiac autoantibodies in patients can be 
reversed and prevented by either humanized monoclonal antibodies similar to mAb 885 or 
competitor compounds specifically designed to inhibit binding of autoantibodies to the celiac 
epitope of TG2, though such a therapeutic benefit may be diminished by pathologic consequences 
of an ongoing gluten-specific T cell activation.  
In conclusion, the present identification of a disease-specific conformational epitope on the 
main autoantigen and its involvement in disease manifestations support the role of autoantibody 
response in disease pathomechanism. These findings may help design further studies to establish 
whether interference with the effects of celiac antibodies would have therapeutic potential.  
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MATERIALS AND METHODS 
Patients 
Serum samples from altogether 216 untreated and 22 treated celiac disease patients (aged 0.9-78 
years) having Marsh grade III villous atrophy were used. Eleven subjects initially had preserved 
small bowel villous architecture but subsequently developed celiac type villous atrophy (early 
stage or latent celiac disease). Included non-celiac controls had normal small bowel villous 
architecture.  
 
Molecular modelling 
Crystal structures of human TG2 (PDB code: 1KV3; ref. 15) and TG3 (PDB code: 1VJJ; ref. 36) 
were used for modelling the full length TG2 as described in details in SI Methods.  
 
Antigens, protein expression and purification  
N-terminally His-tagged TG2 in pET-30 Ek/LIC Vector and domain deletion mutant TG2s were 
generated and purified as described (22). The other TG2 mutations were generated according to the 
QuikChange Site-Directed Mutagenesis Kit (Stratagene) and confirmed by DNA sequencing using 
the ABI PRISM® 3100-Avant Genetic Analyzer. 
 
Anti-TG2 ELISA and competition studies 
The ELISA measurements were performed in duplicates as described previously (13) on Maxisorp 
(Nunc) microtiter plates coated with 0.6 μg TG2 or equimolar amounts of mutants in tris-buffered 
saline containing 5 mM CaCl2 (pH 7.4). Further steps and competition experiments are described 
in details in SI Methods. Standard curves were prepared using dilutions of TG100 monoclonal 
anti-TG2 antibody (NeoMarkers) for each mutant and the binding of other antibodies was 
calculated by 4-parameter fit if binding to wild-type TG2 was 100%.  
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Immunofluorescent studies 
Unfixed frozen sections were incubated with FITC-conjugated anti-human IgA or IgG (DAKO) in 
combination with double labelling for TG2 by anti-TG2 mAbs as described (14). For detecting 
competition, TG2-specific mAbs were added to the tissue for 30 minutes in PBS, and the 
incubation solutions were recollected and tested for patient IgA by ELISA after a purification step 
removing mAbs by protein-G conjugated magnetic beads (Dynabeads).   
 
Human umbilical vein endothelial cells (HUVEC) preparation and cell culture experiments 
HUVECs were prepared and cultured using standard techniques (37). In some experiments the 
cord vein was filled with DyLight 594-conjugated anti-human IgG (Jackson) before cell isolation 
and cells were double-stained after 24h in culture with TG100 anti-TG2 mAb and FITC anti-
mouse antibodies. For the analysis of antibody effects, HUVECs were cultured in matrigel for 24 
hours (SI Methods).  
 
Statistical analysis  
ELISA results were analyzed using GraphPad Prism Software and STATISTICA. For comparison 
of antibody binding to mutant TG2, data were analyzed using repeated measures ANOVA 
followed with Dunnett’s Multiple post test, one way ANOVA followed by Tukey’s post test, or 
Kruskal-Wallis test followed by Dunn’s multiple comparison test as appropriate. A p value < 0.05 
was considered significant.  
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Figure legends  
Figure 1. Binding of celiac IgA serum antibodies (n=7-28) in ELISA to wild-type (Wt) and 
mutant TG2s. Dash indicates median. ***, p<0.001, compared to Wt. S4 contains the combined 
mutations D151N-E153Q-E154Q-E155Q-E158Q (ref.21). Roman numerals indicate presence of 
domains (I-IV).  
Figure 2. Three-dimensional view of TG2 in the closed conformation with the N-terminal β–
sandwich shown in blue, catalytic (core) domain in red, β-barrel 1 in cyan and β-barrel 2 in pink. 
The bound GDP, fibronectin binding site (Asp94, Asp97) and catalytic triad (Cys277, His335, 
Asp358) are represented as ball-and-stick side chains. The amino acids of the putative celiac 
epitope with their lowest distances in Ångström are illustrated as surface representation (frame). 
Figure 3. Binding of serum IgA from 58 celiac children (A) and from 18 celiac adults (B) to TG2 
mutants in ELISA. Bound antibody concentrations were calculated from a calibrator curve 
(Fig.S2E) constructed from the concentration dependent binding of mouse monoclonal anti-TG2 
antibody TG100.  Binding to wild-type (Wt) is 100%. All samples were examined in duplicates. 
Dash indicates median.  p<0.0001 represents significant differences between groups by ANOVA 
test. 433=R433S-E435S (irrelevant control mutant), R=R19S, E=E153S, M=M659S, RM=R19S-
M659S, RE=R19S-E153S, EM= E153S-M659S, REM= R19S-E153S-M659S. 
Figure 4. Binding to mutant TG2 proteins of serum IgA antibodies from patients with early stage 
celiac disease  (•)  without villous atrophy, manifest celiac disease () with small bowel villous 
atrophy (n=11) and  from patients with other autoimmune diseases (n=11) (o), measured by 
ELISA. The binding to wild-type (Wt) was set to 100%. Dash indicates median. ***, p<0.001, ns, 
not significant. R = R19S, RE = R19S-E153S, REM =R19S-E153S-M659S 
Figure 5. Competition effect of mAb885 on the recognition of wild-type TG2 in ELISA by 
antibodies from celiac disease patients (n=6) and from non-celiac autoimmune patients with anti-
TG2 antibodies (n=6). A. Remaining IgA binding in the presence of 18 μg/well mAb885 if the 
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binding without mAb 885 was 100%. Values represent means ± standard errors. B. Comparison of 
the displacing effect of anti-TG2 mAbs 885, CUB7402, TG100 or H23 (18 μg/well) using one of 
the celiac serum samples.  Representative values from three independently performed experiments.  
Figure 6. Tissue binding and biological effects of celiac antibodies mediated by the celiac TG2 
epitope. A. Epitope specificity of serum IgA (1,2), of IgA eluted from celiac tissues (IgA placenta 
3,4) and of passively transferred maternal IgG from newborn serum measured using  mutant TG2 
proteins in ELISA. R=R19S, E=E153S, M=M659S, RE=R19S-E153S, REM= R19S-E153S-
M659S, 433=R433S-E435S. B. Celiac IgA (green) in vivo deposited in the placenta and on the 
surface of chorionic villi (arrows) merge to yellow after incubation of the tissue sections with 
CUB7402 anti-TG2 mAb and double-stained by anti-mouse antibodies (red). After incubation with 
mAb 885 the IgA signal is no more visible and anti-TG2 IgA is detected in the buffer by ELISA. 
No IgA was released by incubation with isotype control mAb (IgG1) or CUB. C. IgA from celiac 
(CD) patients (n=5), autoimmune patients with non-celiac TG2 antibodies (n=6) and biopsied 
antibody-negative controls (n=3) were administered alone or together with mAb 885 to normal 
HUVECs in matrigel and vessel formation was measured. Median lengths of endothelial tubules ±  
SD are shown compared to wells without antibodies set to 100%. ns, not significant; ***, p<0.001. 
E. Morphology of HUVECs in culture from a newborn with prenatally bound maternal celiac IgG 
(red) on their surface (upper and middle) compared to HUVECs prepared from newborn with 
celiac mother on diet and negative for antibodies (lower panel). Bars=50 um. 
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